Advertisement

Topics

Companies Related to "Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure" [Most Relevant Company Matches] - Page: 4 RSS

22:20 EDT 26th March 2019 | BioPortfolio

Here are the most relevant search results for "Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure" found in our extensive corporate database of over 50,000 company records.

Showing "Safety Efficacy Atrasentan With Hormone Naive Prostate Cancer" Companies 76–100 of 4,000+

Relevant

OncoGenex Technologies Inc.

OncoGenex Technologies Inc. (OncoGenex) is a clinical-stage biotechnology company dedicated to improving survival and quality of life of cancer patients by developing targeted therapeutics for treatment-resistant and metastatic cancer. The company's lead drug candidate, OGX-011, has commenced Phase 2 studies in prostate cancer (2), NSCLC and breast cancer. OGX-427 is in preclinical development and...


AmpliMed Corporation

AmpliMed Corporation develops novel drugs for the treatment of cancer. Our lead product, Amplimexon™ (imexon inj.), has particular promise for the treatment of pancreatic cancer, malignant melanoma, lung cancer and multiple myeloma. Other products in our portfolio have promise in ovarian, breast, prostate and other common cancers. Our compounds have novel ways of killing cancer cells which are d...

Abzena plc and Telix Pharmaceuticals Limited

“Radio-immunoconjugates have tremendous potential as one of the most adaptable site specific, precision medicines and, in prostate cancer, PSMA is increasingly recognised as an important target.


AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals is a privately held pharmaceutical company dedicated to the development and commercialization of new therapies for the treatment of pain and other conditions where there is an unmet need for improved safety and efficacy. The company applies its proprietary dosage form and delivery technologies to enhance the safety, therapeutic benefit and commercial attractiveness of curren...

Viramal

Viramal is an emerging specialty pharmaceutical company focused on the development of therapeutics that improve the quality of women’s health. The Company’s well-recognized management team has pioneered market-leading products in fertility and female sexual health, having successfully developed and licensed Crinone®, Replens® and RepHresh®. ...

Vaxon Biotech.

Vaxon Biotech, founded in early 2004 and based in Evry Genopole - France, is a product-driven biopharmaceutical company focusing on the discovery and development of innovative vaccines for the treatment of malignancies, including prostate, lung, breast and colon cancer. The company is based on an original discovery made by Dr. Kostas Kosmatopoulos and his team: optimized cryptic peptides. Vaxon Bi...

Intezyne

Intezyne is dedicated to treating cancer better by offering a new solution to oncologists, who must balance the anti-tumor activity of best-in-class chemotherapeutics with their severe toxicities. Drawing from their expertise in polymer chemistry, the Company’s founders created the IVECT Method to limit chemotherapeutics’ anti-tumor activity to w...

Polynoma, Inc.

Polynoma, Inc. is an oncology-focused biotechnology company based in San Diego, the United States of America. Polynoma’s lead product candidate is the therapeutic vaccine POL 103A for the treatment of melanoma. The Phase 3 trial of POL 103A was initiated based on two randomized, controlled Phase 2 trials that showed statistically significant efficacy ...

Paradigm Therapeutics Ltd

Paradigm Therapeutics was founded in 1999 and has established world class target identification and validation capabilities based on gene knock out technology and in vivo pharmacology. The acquisition of Amedis Pharmaceuticals in January 2005 added key medicinal chemistry skills. The combined company has focused on the identification of novel, small molecule tractable targets with defined therapeu...

Progenics Pharmaceuticals, Inc.

Progenics Pharmaceuticals, Inc., of Tarrytown, NY, is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward supportive care, oncology and virology. Progeni...

GTx, Inc.

GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules that selectively target hormone pathways for the treatment and prevention of cancer, the treatment of side effects of anticancer therapy, cancer supportive care, and other serious medical conditions. ...

DIAMICS, INC

Diamics mission is to work in partnership with both individual and institutional experts to develop and market cost-effective molecular-based cancer screening and diagnostic systems that will increase long-term survival rates through early detection. Cancers that can be detected earlier by screening account for at least half of all new cancer cases.1 In addition to cervical cancer, these cancers ...

Predictive Biosciences

Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. Leveraging a portfolio of patented biomarkers and clinical approaches, the company is building a unique portfolio of assays for cancer management, first targ...

Predictive Biosciences, Inc.

Predictive Biosciences develops novel molecular diagnostic cancer assays and provides molecular pathology services for urology-based practices. Leveraging a portfolio of patented biomarkers and clinical approaches, the company has built a unique portfolio of assays for cancer management, first targeted at bladder and prostate cancer. The company is backed ...

Harpoon Therapeutics, Inc.

Harpoon Therapeutics is an immuno-oncology company founded by Patrick Baeuerle, Ph.D., a pioneer in the development of T-cell engaging therapies, and MPM Capital. The company is focused on the discovery and development of novel T-cell engaging biologics for the treatment of cancer and other diseases. Harpoon Therapeutics created a novel T-cell recruiting d...

Cellanyx Diagnostics

Cellanyx Diagnostics is developing a proprietary living cell phenotypic cancer diagnostic platform to aid clinical decision making. The company’s unique ‘biopsy-on-a-chip’ methodology provides quantitative, actionable assessment of individual cancer cells in biopsy samples using multiple phenotypic biochemical and biophysical markers of tumor ...

Corthera Inc.

Relaxin is a naturally occurring peptide hormone that acts as a systemic and renal vasodilator. Elevated levels of relaxin modulate increases in renal and cardiac function that meet the increased hemodynamic demands of pregnancy. Consistent with this natural role of the hormone, pharmaceutically manufactured relaxin has been shown to have these effects in multiple human studies of men and non-preg...

Winston Pharmaceuticals, Inc.

Winston is a pharmaceutical company focused on pain control which is developing products for large pain control markets, as well as for niche markets, where there are still significant unmet needs for pain management options with improved efficacy, safety, and tolerability profiles. Winston's late stage product candidates include osteo- and rheumatoid arth...

MVI

Wisconsin-based MVI is developing two plasmid DNA vaccines to treat men with prostate cancer. MVI has licensed patented technologies that were developed in the laboratory of Dr. Douglas McNeel at the University of Wisconsin-Madison. More information is available at www.madisonvaccines.com.

GeneSegues

GeneSegues is a biopharmaceutical company built upon advanced, targeted drug delivery technology. We conduct research and early-stage development of proprietary oncology biopharmaceuticals using our ligand-directed, nanoencapsulation technology. Our two initial product candidates are antisense therapeutics for treatment of advanced head neck and prostate cancers. We are currently conducting animal...

PURE Bioscience, Inc.

PURE Bioscience, Inc. develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE’s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and le...

DOBI Medical International, Inc.

DOBI Medical International, headquartered in Mahwah, NJ, is a technology-based medical device company that is developing a unique and potentially lifesaving means for the improved diagnosis of cancer through the detection of abnormal vascularization changes associated with tumors.Our first application of this technology has been to develop an adjunctive tool to mammography - a key diagnostic imagi...

Galil Medical

Ultra-high resolution cryo-surgical device. FDA-approved and effective for prostate cancer, liver cancer and many other applications. System uses needle-probes (1.5mm) to directly freeze localized tissue. 2mm and 3mm probes are available for use in conjunction with IMRI. Galil offers full technical and clinical support for our new-generation cryo system.

BIND Therapeutics, Inc.

BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its medicinal nanoengineering platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND's lead drug candidate, BIND-014, is an...

Smithers Avanza

Smithers Avanza is a contract research organization known for superior quality, on-time delivery, flexibility, and responsiveness. Our laboratories support the pharmaceutical and chemical industries. At our GLP, cGMP, and AAALAC accredited facilities, our Development Services group offers general toxicology, safety pharmacology, vaccine safety testi...


More From BioPortfolio on "Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks